ELAN as reported
Elanco Animal Health Incorporated reported $5.02B of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed.
$5.02B
Revenue, trailing twelve months · to Q2 2026 · +12% against the twelve months before
- Net Income
- −$199M
Net Income · −146% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $379M
Free Cash Flow · +5.0% year on year · trailing twelve months to Q2 2026
- EPS
- −$0.41
EPS · −148% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $5.02B | +12% | Q2 2026 |
| Net Income | −$199M | −146% | Q2 2026 |
| EPS | −$0.41 | −148% | Q2 2026 |
| Gross Margin | 55% | n/a | Q2 2026 |
| Op Margin | 12% | n/a | Q4 2024 · 6 quarters behind |
| Net Margin | −4.8% | n/a | Q2 2026 |
| ROE | −2.4% | n/a | Q2 2026 |
| ROA | −1.2% | n/a | Q2 2026 |
| ROIC | −2.7% | n/a | Q4 2024 · 6 quarters behind |
| Free Cash Flow | $379M | +5.0% | Q2 2026 |
| P/E | 21.4 | n/a | Q2 2025 · 4 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Elanco Animal Health Incorporated (ELAN) - Revenue & ProfitRevenue & ProfitElanco Animal Health Incorporated (ELAN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #1 of 28 by Smart Score